Age-related macular degeneration: Diagnosis and management

British Medical Bulletin

Volumn 85, Issue 1, 2008, Pages 127-149

  Cook, H L ^a   Patel, P J ^a   Tufail, A ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

Age related macular degeneration; Diagnosis; Prophylaxis; Treatment

Indexed keywords

ALPHA INTERFERON; ANECORTAVE; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; STEROID; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN INHIBITOR; VERTEPORFIN;

CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG DOSE COMPARISON; ENDOPHTHALMITIS; HUMAN; LASER COAGULATION; NUTRITIONAL SUPPORT; PHOTODYNAMIC THERAPY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA HEMORRHAGE; RETINA MACULA TRANSLOCATION; RETINA PIGMENT EPITHELIAL CELL TRANSPLANTATION; RETINOTOMY; REVIEW; RISK REDUCTION; SINGLE DRUG DOSE; SMOKING CESSATION; THROMBOEMBOLISM; TRANSPUPILLARY THERMOTHERAPY; TREATMENT INDICATION; TREATMENT OUTCOME; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; BLINDNESS; HUMANS; MACULAR DEGENERATION; MIDDLE AGED;

EID: 40849145527     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldn012     Document Type: Review

References (55)

1. Klein R, Klein BE, Jensen SC, Mares-Perlman JA, Cruickshanks KJ, Palta M. (1999) Age-related maculopathy in a multiracial United States population: the National Health and Nutrition Examination Survey III. Ophthalmology, 106, 1056-1065.
2. Resnikoff S, Pascolini D, Etya'ale D et al. (2004) Global data on visual impairment in the year 2002. Bull World Health Organ, 82, 844-851.
3. Klein R, Klein BE, Jensen SC, Meuer SM (1997) The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology, 104, 7-21.
4. Friedman DS, O'Colmain BJ, Munoz B et al. (2004) Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol, 122, 564-572.
5. Varma R, Fraser-Bell S, Tan S, Klein R, Azen SP (2004) Prevalence of age-related macular degeneration in Latinos: the Los Angeles Latino eye study. Ophthalmology, 111, 1288-1297.
6. Klein R, Peto T, Bird A, Vannewkirk MR (2004) The epidemiology of age-related macular degeneration. Am J Ophthalmol, 137, 486-495.
7. Tomany SC, Wang JJ, Van LR et al. (2004) Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. Ophthalmology, 111, 1280-1287.
8. Schmidt S, Hauser MA, Scott WK et al. (2006) Cigarette smoking strongly modifies the association of LOC387715 and age-related macular degeneration. Am J Hum Genet, 78, 852-864.
9. Klein RJ, Zeiss C, Chew EY et al. (2005) Complement factor H polymorphism in age-related macular degeneration. Science, 308, 385-389.
10. Edwards AO, Ritter R III, Abel KJ, Manning A, Panhuysen C, Farrer LA (2005) Complement factor H polymorphism and age-related macular degeneration. Science, 308, 421-424.
11. Haines JL, Hauser MA, Schmidt S et al. (2005) Complement factor H variant increases the risk of age-related macular degeneration. Science, 308, 419-421.
12. Magnusson KP, Duan S, Sigurdsson H et al. (2006) CFH Y402H confers similar risk of soft drusen and both forms of advanced AMD. PLoS Med, 3,e5.
13. Sepp T, Khan JC, Thurlby DA et al. (2006) Complement factor H variant Y402H is a major risk determinant for geographic atrophy and choroidal neovascularization in smokers and nonsmokers. Invest Ophthalmol Vis Sci, 47, 536-540.
14. Souied EH, Leveziel N, Richard F et al. (2005) Y402H complement factor H polymorphism associated with exudative age-related macular degeneration in the French population. Mol Vis, 11, 1135-1140.
15. Okamoto H, Umeda S, Obazawa M et al. (2006) Complement factor H polymorphisms in Japanese population with age-related macular degeneration. Mol Vis, 12, 156-158.
16. Gold B, Merriam JE, Zernant J et al. (2006) Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet, 38, 458-462.
17. Jakobsdottir J, Conley YP, Weeks DE, Mah TS, Ferrell RE, Gorin MB (2005) Susceptibility genes for age-related maculopathy on chromosome 10q26. Am J Hum Genet, 77, 389-407.
18. Rivera A, Fisher SA, Fritsche LG et al. (2005) Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet, 14, 3227-3236.
19. Anonymous (1982) Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol, 100, 912-918.
20. Macular Photocoagulation Study Group (1991) Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol, 109, 1109-1114.
21. Macular Photocoagulation Study Group (1994) Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Arch Ophthalmol, 112, 500-509.
22. Macular Photocoagulation Study Group (1993) Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Arch Ophthalmol, 111, 1200-1209.
23. Freund KB, Yannuzzi LA, Sorenson JA (1993) Age-related macular degeneration and choroidal neovascularization. Am J Ophthalmol, 115, 786-791.
24. Wormald R, Evans J, Smeeth L, Henshaw K (2005) Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev, CD002030.
25. Bressler NM (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol, 119, 198-207.
26. Verteporfin in Photodynamic Therapy Study Group (2001) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - verteporfin in photodynamic therapy report 2. Am J Ophthalmol, 131: 541-560.
27. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med, 351, 2805-2816.
28. D'Amico DJ, Masonson HN, Patel M et al. (2006) Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology, 113, 992-1001.
29. Brown DM, Kaiser PK, Michels M et al. (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med, 355, 1432-1444.
30. Rosenfeld PJ, Brown DM, Heier JS et al. (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med, 355, 1419-1431.
31. Brown DM (2007) PIER study data. Retinal Physician 2006 Symposium.
32. Fung AE, Lalwani GA, Rosenfeld PJ et al. (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol, 143, 566-583.
33. Spaide RF, Laud K, Fine HF et al. (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina, 26, 383-390.
34. Gillies MC, Simpson JM, Luo W et al. (2003) A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol, 121, 667-673.
35. Spaide RF, Sorenson J, Maranan L (2003) Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology, 110, 1517-1525.
36. D'Amico DJ, Goldberg MF, Hudson H et al. (2003) Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmology, 110, 2372-2383.
37. Slakter JS, Bochow TW, D'Amico DJ et al. (2006) Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology, 113, 3-13.
38. Sivagnanavel V, Evans JR, Ockrim Z, Chong V (2004) Radiotherapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev, CD004004.
39. Pharmacological Therapy for Macular Degeneration Study Group (1997) Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebo-controlled clinical trial. Arch Ophthalmol, 115, 865-872.
40. Hawkins BS, Bressler NM, Miskala PH et al. (2004) Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings: SST report no. 11. Ophthalmology, 111, 1967-1980.
41. Binder S, Krebs I, Hilgers RD et al. (2004) Outcome of transplantation of autologous retinal pigment epithelium in age-related macular degeneration: a prospective trial. Invest Ophthalmol Vis Sci, 45, 4151-4160.
42. MacLaren RE, Uppal GS, Balaggan KS et al. (2007) Autologous transplantation of the retinal pigment epithelium and choroid in the treatment of neovascular age-related macular degeneration. Ophthalmology, 114, 561-570.
43. Bressler NM, Bressler SB, Childs AL et al. (2004) Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report no. 13. Ophthalmology, 111, 1993-2006.
44. Hassan AS, Johnson MW, Schneiderman TE et al. (1999) Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement. Ophthalmology, 106, 1900-1906.
45. Aisenbrey S, Lafaut BA, Szurman P et al. (2002) Macular translocation with 360 degrees retinotomy for exudative age-related macular degeneration. Arch Ophthalmol, 120, 451-459.
46. Toth CA, Freedman SF (2001) Macular translocation with 360-degree peripheral retinectomy impact of technique and surgical experience on visual outcomes. Retina, 21, 293-303.
47. Gelisken F, Voelker M, Schwabe R et al. (2007) Full macular translocation versus photodynamic therapy with verteporfin in the treatment of neovascular age-related macular degeneration: 1-year results of a prospective, controlled, randomised pilot trial (FMT-PDT). Graefes Arch Clin Exp Ophthalmol, 245, 1085-1095.
48. Fujii GY, de Juan E Jr, Pieramici DJ et al. (2002) Inferior limited macular translocation for subfoveal choroidal neovascularization secondary to age-related macular degeneration: 1-year visual outcome and recurrence report. Am J Ophthalmol, 134, 69-74.
49. Age-related Eye Disease Study Research Group (2001) A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol, 119, 1417-1436.
50. Olk RJ, Friberg TR, Stickney KL et al. (1999) Therapeutic benefits of infrared (810-nm) diode laser macular grid photocoagulation in prophylactic treatment of nonexudative age-related macular degeneration: two-year results of a randomized pilot study. Ophthalmology, 106, 2082-2090.
51. Ho AC, Maguire MG, Yoken J et al. (1999) Laser-induced drusen reduction improves visual function at 1 year. Choroidal Neovascularization Prevention Trial Research Group. Ophthalmology, 106, 1367-1373.
52. Hudson HL, Lane SS, Heier JS et al. (2006) Implantable miniature telescope for the treatment of visual acuity loss resulting from end-stage age-related macular degeneration: 1-year results. Ophthalmology, 113, 1987-2001.
53. Macular Photocoagulation Study Group (1997) Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Arch Ophthalmol, 115, 741-747.
54. Regillo CD (2003) Laser treatment in fellow eyes with large drusen: updated findings from a pilot randomized clinical trial. Ophthalmology, 110, 971-978.
55. Augustin AJ, Schmidt-Erfurth U (2006) Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology, 113, 14-22.